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ART ICLE Open Ac ce s s
Grainyhead-like 2 (GRHL2) knockout
abolishes oral cancer development
through reciprocal regulation of the MAP
kinase and TGF-β signaling pathways
Wei Chen1, Kyung L. Kang1,2, Abdullah Alshaikh1, Saaket Varma1, Yi-Ling Lin3, Ki-Hyuk Shin1,4,5, Reuben Kim1,5,
Cun-Yu Wang4,5, No-Hee Park1,5,6, Katharina Walentin7, Kai M. Schmidt-Ott7 and Mo K. Kang 1,4,5
Abstract
Grainyhead-Like 2 (GRHL2) is an epithelial-specific transcription factor that regulates epithelial morphogenesis and
differentiation. Prior studies suggested inverse regulation between GRHL2 and TGF-β in epithelial plasticity and
potential carcinogenesis. Here, we report the role of GRHL2 in oral carcinogenesis in vivo using a novel Grhl2 knockout
(KO) mouse model and the underlying mechanism involving its functional interaction with TGF-β signaling. We
developed epithelial-specific Grhl2 conditional KO mice by crossing Grhl2 floxed mice with those expressing CreER
driven by the K14 promoter. After induction of Grhl2 KO, we confirmed the loss of GRHL2 and its target proteins, while
Grhl2 KO strongly induced TGF-β signaling molecules. When exposed to 4-nitroquinoline 1-oxide (4-NQO), a strong
chemical carcinogen, Grhl2 wild-type (WT) mice developed rampant oral tongue tumors, while Grhl2 KO mice
completely abolished tumor development. In cultured oral squamous cell carcinoma (OSCC) cell lines, TGF-β signaling
was notably induced by GRHL2 knockdown while being suppressed by GRHL2 overexpression. GRHL2 knockdown or
KO in vitro and in vivo, respectively, led to loss of active p-Erk1/2 and p-JNK MAP kinase levels; moreover, ectopic
overexpression of GRHL2 strongly induced the MAP kinase activation. Furthermore, the suppressive effect of GRHL2 on
TGF-β signaling was diminished in cells exposed to Erk and JNK inhibitors. These data indicate that GRHL2 activates
the Erk and JNK MAP kinases, which in turn suppresses the TGF -β signaling. This novel signaling represents an
alternative pathway by which GRHL2 regulates carcinogenesis, and is distinct from the direct transcriptional regulation
by GRHL2 binding at its target gene promoters, e.g., E-cadherin, hTERT, p63, and miR-200 family genes. Taken together,
the current study provides the first genetic evidence to support the role of GRHL2 in carcinogenesis and the
underlying novel mechanism that involves the functional interaction between GRHL2 and TGF-β signaling through the
MAPK pathways.
Introduction
Grainyhead-like 2 (GRHL2) is one of the three known
mammalian homologs of Drosophila Grainyhead (GRH),
along with GRHL1 and GRHL3, which are involved in
epithelial regeneration and function1–3. In addition, we
have demonstrated that GRHL2 plays a unique role in
control of cellular proliferation and differentiation
through transcriptional regulation of its target genes, e.g.,
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hTERT, p63, and epidermal differentiation complex
(EDC) genes4–6. GRHL2 regulates keratinocyte prolifera-
tion; its level declines during replicative senescence or
stress-induced senescence, while ectopic GRHL2 expres-
sion increases cellular lifespan4. Hence, loss of GRHL2
during senescence may lead to reduced hTERT/telomer-
ase activity, resulting in accelerated telomeric attrition
and aging. In addition, GRHL2 is a critical determinant of
the epithelial phenotype through transcriptional regula-
tion of the relevant effector molecules, e.g., miR-200
family genes and ZEB1, which also determine cellular
plasticity7–9. GRHL2 has been shown to suppress
epithelial–mesenchyme transition (EMT) induced by
TGF-β in human mammary epithelial cells9, while the
mechanisms underlying the functional interaction
between GRHL2 and TGF-β are not known.
TGF-β is a growth factor that binds to the TGF-β
receptors (types I/II) through auto/paracrine mechanisms
and activates transcription cofactors, e.g., Smad2/3 by
phosphorylation and nuclear translocation of p-Smad2/3
and Smad4 complex10. TGF-β is generally considered a
potent growth inhibitor of epithelial cells through
induction of diverse cell cycle inhibitory proteins. Hence,
it is considered a strong tumor suppressor during the
early stage of oral carcinogenesis11–13. TGF-β also exhi-
bits malignant effects in established cancers through the
induction of EMT and metastasis14, 15. Thus, TGF-β
demonstrates dual roles in the cancer phenotype, which
depends in part on the stage of the disease progression.
The current study investigated the functional interac-
tion between GRHL2 and TGF-β signaling and the
underlying molecular mechanism. Using epithelial-
specific Grhl2 conditional knockout (cKO) mice, we
demonstrate the inhibitory effects of GRHL2 on TGF-β
signaling in the epidermis and oral mucosa. Grhl2 KO did
not cause gross phenotypic defects in the epithelia,
Fig. 1 Grhl2 KO suppresses epithelial phenotype marker genes and induces TGF-β signaling in epithelial tissues in vivo. a Western blotting
was performed with epidermal tissues isolated from Grhl2 WT and Grhl2 KO mice for GRHL2 and various target proteins, e.g., PCNA, p63, K14, and
Sox2, as well as TGF-β and p-Smad3. b Western blotting signals were quantitated by densitometric analysis and plotted with the mean values for
Grhl2 WT and KO mice groups. Bar indicates mean/SD, *Po 0.05. c Quantitative reverse transcription-PCR (qRT-PCR) was performed with total RNAs
isolated from Grhl2 WT, Grhl2 heterozygote (±) and Grhl2 KO mouse epidermis. Data were derived from three independent experiments and qRT-PCR
assays were performed in triplicates. d IFS was performed for GRHL2 and E-Cad in skin epithelia of Grhl2 WT and KO mice. e IFS signals were
quantitated and plotted with the mean values for Grhl2 WT and KO mice groups. f qRT-PCR was performed with tongue epithelium harvested from
Grhl2 WT mice (n= 3) and Grhl2 KO mice (n= 3) for various markers of mesenchyme, e.g., N-Cad, α-SMA, ZEB1, and ZEB2. Bar indicates mean/SD. *P
o 0.05, statistical significance, compared with WT mice
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although there was reduced cell proliferation at the basal
cell layers. However, Grhl2 KO completely abolished the
tongue tumor formation after chronic exposure to the
chemical carcinogen 4-nitroquinoline 1-oxide (4-NQO),
which led to rampant tongue cancer development in the
wild-type (WT) mice. Mechanistic investigation revealed,
for the first time, that GRHL2 is necessary and sufficient
for activation of the Erk1/2 and JNK MAP kinases, which
then suppress TGF-β signaling. Taken together, the cur-
rent study demonstrates evidence for the functional
interaction between GRHL2 and TGF-β signaling through
MAP kinase pathways, and provides the first genetic
evidence to support the role of GRHL2 in the early onset
of oral carcinogenesis using the Grhl2 cKO model.
Results
Grhl2 KO abolishes chemical carcinogen-induced oral
carcinogenesis
In order to determine the role of GRHL2 in epithelial
tissue regeneration and oral carcinogenesis in vivo, we
generated Grhl2 cKO mice by crossing Grhl2 floxed (fl/fl)
and K14-CreERT, denoted K14/Grhl2 cKO, which allows
for conditional deletion of Grhl2 by exposure to tamox-
ifen (Tmx) in an epithelial tissue-specific manner. The
resulting mice (Grhl2 KO) showed absence of GRHL2
expression and downregulation of the GRHL2 target
genes, e.g., E-cadherin (E-Cad), PCNA, p63, and TERT
(Fig. 1a-c), in the excised skin samples. Upon induction of
the Cre expression, loss of GRHL2 and E-Cad expression
was detected by immunofluorescence staining (IFS) in the
skin epithelia of the Grhl2 KO mice (Fig. 1d, e). On the
other hand, the levels of TGF-β1 and p-Smad3 were
notably increased by Grhl2 KO, suggesting the reciprocal
link between GRHL2 and TGF-β1 signaling, although it
remains unknown whether TGF-β and p-Smad levels
were contributed by epidermis or dermis layers, or both.
With Grhl2 KO, there was also strong induction of
mesenchymal markers, e.g., N-cadherin (N-Cad), α-SMA,
ZEB1, and ZEB2, in the tongue tissue compared with
those of the WT mice, consistent with induction of TGF-
β signaling (Fig. 1f).
Histologically, Grhl2 KO mice exhibited reduced cel-
lularity at the basal layers of dorsal tongue epithelium and
skin, while maintaining the intact epithelial layers
(Fig. 2a). In addition, BrdU incorporation in the basal cell
layer of dorsal tongue epithelium was significantly
reduced by Grhl2 KO compared to the WT mice (Fig. 2b),
indicating reduced cell proliferation and tissue regenera-
tion by Grhl2 KO. IFS confirmed complete disruption of
GRHL2 expression and significant reduction of GRHL2
target genes, E-Cad and K14, in tongue of Grhl2 KO mice
(Fig. 2c, d). These findings demonstrate that conditional
KO of Grhl2 in stratified epithelium suppressed cell
proliferation at the basal cell layer but does not cause
gross phenotypic defects in the normal epithelial tissues.
Our prior study showed the role of GRHL2 in estab-
lished human oral cancers using in vitro models7. In the
current study, we used the Grhl2 KO model to determine
the role of GRHL2 in the early stage of oral carcinogenesis
in vivo by chronic exposure of mice to 4-NQO. Exposure
of oral cavity to drinking water containing varying dose
(15–50 μg/ml) of 4-NQO yields precancerous and can-
cerous lesions on the tongue, oral mucosa, and esophagus
with similar molecular pathologic profiles as human oral
squamous cell carcinomas (OSCCs)16, 17. K14/Grhl2 cKO
mice were treated with Tmx (75 mg/kg) at three different
time points, as illustrated in Fig. 3a, to induce Grhl2 KO
while the mice were exposed to 16 weeks of 4-NQO. After
16 weeks of 4-NQO treatment, Grhl2 WT mice exhibited
gross tumor nodule formation on the tongue, while Grhl2
Fig. 2 Epithelial-specific Grhl2 KO leads to retarded basal cell proliferation without gross histological defects in the epithelium. a Histology
was shown after hematoxylin and eosin (H&E) staining of tongue epithelia (dorsal and ventral surfaces) and skin of Grhl2 WT and KO mice. b Grhl2 WT
and KO mice were labeled with BrdU and the nuclear incorporation was determined by IHC of dorsal tongue epithelium. BrdU-positive cells were
counted in each field and plotted as % of all basal cells. Bar indicates mean/SD. *P o 0.05, statistical significance, compared with WT mice. c IFS was
performed for GRHL2, E-Cad, FN, and K14 in dorsal tongue epithelia of Grhl2 WT and KO mice. d IFS signals were quantitated and plotted with the
mean values for Grhl2 WT and KO mouse groups. Bar indicates mean/SD. *Po 0.05, statistical significance, compared with WT mice
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KO mice (Tmx1) displayed complete absence of tumor
nodule formation (Fig. 3b, Table 1). In addition, admin-
istration of Tmx after 4 and 16 weeks into the 4-NQO
exposure (designated as Tmx2 and Tmx3, respectively)
also resolved the severity and quantity of oral lesions,
revealed by toluidine blue staining (Fig. 3c). Comparison
of multiplicity of tumors in each group revealed sig-
nificant differences between Grhl2 WT mice vs. the KO
mice in Tmx1, Tmx2, and Tmx3 groups (Table 1).
Histologically, 4-NQO treatment of Grhl2 WT mice
induced the formation of polypoid masses with significant
cytological atypia, a high mitotic index, and widespread
Fig. 3 Grhl2 KO prevents chemical carcinogen-induced tongue carcinogenesis. a Grhl2 KO was induced by tamoxifen (Tmx, 75 mg/kg)
administration for 7 consecutive days, immediately prior to 4-NQO (30 μg/ml) exposure (Tmx1, n= 6), after 4-week exposure to 4-NQO (Tmx2, n= 3),
or after 16 weeks of 4-NQO exposure (Tmx3, n= 3). These WT mice (n= 7) and KO mice (total n= 12) were all exposed to 4-NQO for 4 months, and
then maintained for additional 6 weeks in drug-free drinking water before they were killed. For comparison, we also included Grhl2 WT (n= 5) and
KO (n= 5) mice exposed to DMSO, which did not elicit tumor development in any mice. b Grhl2 WT and KO (Tmx1) tongues were harvested and
stained with 0.1% toluidine blue after exposure to 4-NQO for 16 weeks, and representative specimens are shown. c Grhl2 WT and KO (Tmx2 and
Tmx3) tongues were stained with 0.1% toluidine blue after 4-NQO exposure. Representative staining results were shown for tongues of mice in
various groups
Table 1 Tumor nodule formation on tongue epithelium in mice exposed to 4-NQO
Group Treatment na Tamoxifen (week)b Multiplicity of tumor (MOT) per tonguec P valuesd
Grhl2 WT DMSO 5 None 0 NA
Grhl2 WT 4-NQO 7 None 3.6 NA
Grhl2 KO/Tmx1 DMSO 5 −1 0 NA
Grhl2 KO/Tmx1 4-NQO 6 −1 0 0.0015
Grhl2 KO/Tmx2 4-NQO 3 4 0.4 0.0139
Grhl2 KO/Tmx3 4-NQO 3 16 0.7 0.0260
aNumber of mice per group
bTamoxifen was given for 7 consecutive days to create Grhl2 KO. Number shown represents the timing at which Tamoxifen was given with respect to start of 4-NQO
treatment
cMOT was calculated by counting the number of visible tumors on the dorsum tongue per mouse
dNon-parametric Wilcoxon rank-sum test was performed for each group against those of Grhl2 WT mice treated with 4-NQO
NA not applicable
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dysplastic changes in the epithelium, while tongues from
both Grhl2 WT and KO mice exposed to dimethylsulf-
oxide (DMSO) exhibited similar histology with normal
squamous epithelium (Fig. 4a). Figure 4b shows a carci-
nomatous mass on the dorsal tongue of Grhl2 WT mouse
exposed to 4-NQO. The mass is composed of malignant
epithelial islands and appears to be invading the muscle
layer. In contrast, the carcinogenic effect of 4-NQO was
greatly reduced by Grhl2 KO. When Grhl2 was knocked
out prior to 4-NQO treatment (Tmx1), the carcinogen
only resulted in a slightly thicker epithelium (Fig. 4b). The
differentiation of the surface epithelium was mostly nor-
mal, although focal and very mild cellular alterations were
noted on the ventral tongue of some mice. When Grhl2
was knocked out 4 weeks into 4-NQO treatment (Tmx2),
the epithelium developed multifocal mild to moderate
epithelial dysplasia with a higher mitotic index. When the
gene was knocked out after 16 weeks of 4-NQO treatment
(Tmx3), the epithelium developed widespread dysplastic
changes and formation of polypoid masses. The masses
were generally smaller than those observed in the Grhl2
WT mice and there was no connective tissue invasion
noted in samples evaluated. It suggested that Grhl2 KO in
Tmx3 treatment might still be able to provide some
protection again 4-NQO-induced carcinogenesis.
Chronic oral exposure to 4-NQO led to strong nuclear
staining for GRHL2 in Grhl2 WT tumor revealed by
immunohistochemistry (IHC), while the tongue epithe-
lium apparently lacked such staining in Grhl2 KO mice
administered with Tmx at all time points (Fig. 4c, d).
Likewise, the expression of GRHL2 target proteins, e.g.,
Oct-4 and p63, were readily detectable in Grhl2 WT
tongue tumor but were significantly suppressed in Grhl2
KO tissues even exposed to 4-NQO for 4 months (Fig. 4c,
d). Western blotting of the tongue tissues confirmed
induction of GRHL2 target genes, e.g., TERT and PCNA,
after 4-NQO exposure in Grhl2 WT mice, but these
proteins were suppressed in Grhl2 KO mice. The tongue
tissues from Grhl2 KO mice demonstrated strong eleva-
tion of the levels in TGF-β, p-Smad3, and Smad4 com-
pared with those from the WT mice (Supplement
Figure S1). These data indicate that GRHL2 expression is
required for chemical carcinogen-induced oral cancer
development in vivo.
GRHL2 is required for suppression of TGF-β signaling and
MAP kinase activation in OSCC cells
A previous study showed the inhibitory role of GRHL2
in TGF-β signaling8, which is considered as tumor-
suppressive during the early stage of carcinogenesis, in
part due to its growth-inhibitory and apoptotic effects18.
Our in vivo data also demonstrate the reciprocity between
GRHL2 and TGF-β signaling, as the levels of TGF-β and
p-Smad3 were elevated in Grhl2 KO mice (Fig. 1). To
explore the mechanism by which GRHL2 regulates TGF-β
signaling and tumor development, we performed in vitro
experiments using established OSCC cell lines, SCC4,
SCC15, and BaP-T with stable GRHL2 knockdown
through infection with various GRHL2 short hairpin RNA
(shRNA) vectors targeting different sequences (pLL3.7-
ShGRHL2 for SCC4 and LKO.1-ShGRHL2-1, 2, and 3 for
SCC15 and BaP-T; Fig. 5a, b, Supplement Figure S2).
Fig. 4 Grhl2 KO suppresses 4-NQO-induced histopathology in tongue tumors. a Gross morphology of tongues from Grhl2 WT and KO mice
exposed to DMSO were shown without altered morphology or histology of the tongue epithelium. b In Grhl2 WT mice treated with 4-NQO, polypoid
masses and widespread dysplastic changes are present. A higher-power view shows that the mass is composed of proliferating malignant epithelial
islands and has invaded the underlying muscle layer. Keratin formation and a high mitotic index are obvious. Tongue sections from Grhl2 KO Tmx1
mice show slightly thickened surface epithelium on the tongue. The differentiation is mostly within normal limits. Tongue sections from Grhl2 KO
Tmx2 mice show epithelial hyperplasia with multifocal mild to moderate epithelial dysplasia. Tongue sections from Grhl2 KO Tmx3 mice show
extensive epithelial hyperplasia with widespread dysplastic changes and formation of polypoid masses. Invasion was not noted in any of the Grhl2 KO
mice examined. c IHC was performed with tongue tissues from Grhl2 WT and KO (Tmx1, Tmx2, and Tmx3) mice after 4-NQO exposure for GRHL2, Oct-
4, and p63. Nuclei were stained with DAPI. d IFS signals were quantitated and plotted with the mean values for Grhl2 WT and different KO mouse
groups after exposure to 4-NQO. Bar indicates mean/SD. *P o 0.05, statistical significance, compared with WT mice
Chen et al. Oncogenesis  (2018) 7:38 Page 5 of 12
Oncogenesis
These cells were used because they highly express endo-
genous GRHL2. BaP-T was included herein as a cell line
that harbors HPV type 16 DNA19. GRHL2 shRNA for
SCC4 was fully characterized in our previous study20. As
expected, GRHL2 knockdown led to increased expression
of TGF-β signaling molecules, e.g., p-Smad2/3 and
Smad4, as well as TGF-β downstream proteins, e.g., col-
lagen 1a1 (Col1a1) and α-SMA (Fig. 5a, b, d). IFS staining
also suggested that loss of GRHL2 elevated TGF-β-
signaling molecules in SCC4 cells (Fig. 5f, g). In SCC9 and
FaDu cells, which lack endogenous GRHL2 expression,
GRHL2 overexpression led to suppression of TGF-β, p-
Smad2/3, and Smad4 levels, as well as TGF-β target genes,
Col1a1, Col3a1, and α-SMA (Fig. 5c, e, Supplement Fig-
ure S3). These results demonstrate the inhibitory effects
of GRHL2 in TGF-β signaling in human OSCC cells.
To explore the underlying mechanism by which
GRHL2 suppressed the TGF-β pathway, we assessed the
role of GRHL2 in activation of the mitogen-activated
protein (MAP) kinase signaling, e.g., Erk, JNK, and p38.
Prior studies showed functional interaction between MAP
kinase and TGF-β signaling pathways, and that Erk pro-
teins blocked nuclear translocation of Smad proteins
upon TGF-β activation and induce repressive Smad721–23.
With GRHL2 knockdown in SCC4 and SCC15 cells, there
was complete absence of p-Erk1/2 and p-JNK, while p38
Fig. 5 GRHL2 regulates TGF-β signaling in OSCC cells. a, b Western blotting was performed for TGF-β signaling and the target proteins, e.g., p-
Smad2, p-Smad3, Smad4, Col1a1, and α-SMA, in whole-cell extracts of SCC4 and BaP-T cells infected with control lentiviral vectors (ShContr or LKO.1)
or those expressing GRHL2 shRNA targeting different regions (ShGRHL2 and ShGRHL2-1,2,3). c GRHL2 was overexpressed in SCC9 and FaDu cell lines
infected with retroviral vector expressing full-length cDNA of GRHL2 (LXSN-GRHL2) or the empty vector (LXSN) for GRHL2 and TGF-β signaling
proteins, e.g., TGF-β, p-Smad2, p-Smad3, Smad4, Col1a1, Col3a1, and α-SMA. d qRT-PCR was performed for Col1a1 and Col3a1 in SCC4 and SCC15
cells after GRHL2 knockdown using the lentiviral vector (ShGRHL2). *P o 0.05, significant difference. e qRT-PCR was performed in SCC9 and FaDu
cells after GRHL2 overexpression for Col1a1 and Col3a1. f IFS was performed for GRHL2, Col1a1, p-Smad2, Smad4, and p-Erk1/2 in SCC4 cells stably
infected with Lenti-ShGRHL2 or the control vector (ShContr). g IFS signals were quantitated and plotted with the mean values for SCC4 cells with
Grhl2 knockdown and its control cells. Bar indicates mean/SD. *P o 0.05, significant difference, compared with SCC4 infected with control vector
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phosphorylation was increased in SCC4 (Fig. 6A). IFS
staining of SCC4/ShGRHL2 cells also revealed diminution
of p-Erk1/2 staining in cells (Fig. 5). Thus, GRHL2 may
regulate Erk and JNK activation in the MAP kinase-
signaling cascade.
With GRHL2 knockdown, the level of phosphorylated
p65, indicative of active NF-κB, was notably increased, in
SCC4 and SCC15 cells, concomitant with loss of p-Erk
(Fig. 6a). In a cell fractionation experiment, GRHL2
knockdown abolished the p-Erk1/2 level in both cyto-
plasmic and nuclear fractions, and led to elevated p65
phosphorylation in the nuclear fraction (Fig. 6b). Since
Erk1/2 is known to suppress NF-κB activation24, 25, these
data further support our finding that GRHL2 plays a role
in maintaining the phosphorylation state of Erk1/2 and
active MAP kinase signaling. We also surveyed the level of
p-Erk1/2 and p-JNK in the tongue tumor tissues in Grhl2
WT and KO mice exposed to 4-NQO. In both WT and
KO mice treated with DMSO, p-Erk1/2 and p-JNK
staining was weakly detectable in the tongue epithelium.
However, 4-NQO treatment for 16 weeks strongly
induced the level of staining in the Grhl2 WT tissues. The
tongue epithelium from Grhl2 KO mice did not show
induction of p-Erk1/2 or p-JNK staining even with 4-
Fig. 6 GRHL2 regulates Erk and JNK activation in OSCC cells. a In SCC4 and SCC15 cell lines with GRHL2 knockdown, western blotting was
performed for p-Erk1/2, p-JNK, p-p38, and p-p65. b SCC4 and SCC15 cells with GRHL2 knockdown (ShGRHL2) and the control cells (ShContr) were
fractionated into cytoplasmic and nuclear fractions, and western blotting was performed for p-Erk1/2 and p-p65. p84 was used as marker for nuclear
fraction, while GAPDH was used as cytoplasmic loading control. c, d Tongue epithelium from Grhl2 WT and KO mice exposed to 4-NQO for 16 weeks
was stained for p-Erk1/2, p-JNK, and Smad4 by IHC. IHC-positive cells were counted in each field and plotted as % of all cells. Bar indicates mean/SD.
*Po 0.05, statistical significance, compared with WT mice
Fig. 7 GRHL2 suppresses TGF-β signaling through activation of Erk and JNK MAP kinases. a SCC9 cells infected with retroviral vector
expressing GRHL2 or the empty control vector (LXSN) were exposed to U0126 (10 μM) for 24 h, and western blotting was performed for GRHL2, p-
Erk1/2, Smad4, and C3a1 (upper panels). SCC9/GRHL2 cells were exposed to SP600125 (20 μM) and western blotting was performed for p-JNK and
Col1a3 (bottom panels). b NHOF infected with retroviral vector expressing GRHL2 or the empty vector (LXSN) were exposed to MAPK inhibitors,
SP600125 (20 μM), U0126 (10 μM), or PD98059 (20 and 50 μM), for 24 h and western blotting was performed for GRHL2, p-Erk1/2, p-JNK, and TGF-β
target genes (Col3a1, Col1a1, and Smad4). GAPDH was used as loading control for all western blotting analyses. c IFS was performed for Smad4 and
Col3a1 in SCC9/LXSN or SCC9/GRHL2 cells exposed to DMSO (as controls), U0126 (10 μM), SP600125 (20 μM), or PD98059 (50 μM) for 24 h. d IFS
signals were quantitated and plotted with the mean values. Bar indicates mean/SD. *Po 0.05, statistical significance, compared with SCC9/GRHL2
cells exposed to DMSO
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NQO treatment (Fig. 6c, d). Smad4 was induced in tongue
epithelium from Grhl2 KO mice compared to WT mice,
whereas 4-NQO exposure diminished the Smad4
expression in mice with or without Grhl2 KO. Western
blotting of tongue tissues also revealed strong elevation of
the TGF-β level in Grhl2 KO tissues (Supplement Fig-
ure S1). Thus, 4-NQO-induced oral carcinogenesis leads
to MAP kinase activation in tongue epithelium, only in
the presence of GRHL2 expression, in part through sup-
pressing TGF-β signaling.
Inhibition of MAP kinase signaling reverses the
suppressive effect of GRHL2 on TGF-β signaling
To test the functional role of GRHL2 in the crosstalk
between the TGF-β signaling and MAP kinase signaling
pathways, we inhibited p-Erk1/2 in SCC9 cells in which
GRHL2 was overexpressed. With exogenous GRHL2,
there was clear induction of p-Erk1/2 in SCC9, confirm-
ing the positive effects of GRHL2 on the MAP kinase
pathway, and suppression of TGF-β signaling molecules,
Smad4 and Col3a1 (Fig. 7a). Upon exposure to MEK1/2
inhibitor (U0126), p-Erk1/2 was abolished in cells,
and Smad4 and Col3a1 levels were induced, even in the
presence of GRHL2 overexpression (SCC9/GRHL2).
IFS staining of cells further confirmed re-expression of
Smad4 and Col3a1 in SCC9/GRHL2 cells after various
MAP kinase inhibitors (U0126, SP600125, and PD9859;
Fig. 7c, d).
Ectopic overexpression of GRHL2 in primary NHOF
(NHOF/GRHL2) led to increased p-Erk1/2 and p-JNK
levels, yet reduced Col3a1, Col1a1 and Smad4 level
(Fig. 7b). NHOF was utilized herein because it lacks
endogenous GRHL2 expression. We then exposed
NHOF/GRHL2 cells to the MAP kinase inhibitors, and
assessed the effects on TGF-β signaling, e.g., Smad4,
Col3a1, and Col1a1. GRHL2 overexpression in NHOF
strongly elevated Erk/JNK phosphorylation and sup-
pressed TGF-β signaling. However, when the Erk/JNK
phosphorylation was blocked by the MAP kinase inhibi-
tors, there was re-activation of TGF-β signaling molecules
in the presence of GRHL2 overexpression. These novel
findings indicate that the inhibitory effect of GRHL2 on
TGF-β signaling involves activation of the Erk and JNK
signaling of the MAP kinase pathways.
Discussion
Using the novel epithelial-specific Grhl2 cKO model, we
confirmed the concurrent downregulation of GRHL2
targets and epithelial-specific proteins, e.g., PCNA, p63, β-
Cat, K14, and Sox2, as well as upregulation of TGF-β-
signaling molecules, e.g., TGF-β1, Smad4, and p-Smad3.
Surprisingly, the steady-state histomorphology of cuta-
neous and oral epithelium remained intact after Grhl2
KO, although the tissues demonstrated reduced epithelial
thickness and cell mitotic activity. Our current finding
using the Grhl2 cKO model is the first genetic evidence to
support the role of GRHL2 in primary tumor develop-
ment from normal oral epithelia. Furthermore, Grhl2 KO
lowered the severity of the tongue lesions compared with
Grhl2WT mice even after 4 months' exposure to 4-NQO.
Hence, the data support the preventive and mitigative
effects of Grhl2 KO on oral dysplastic lesions, and this
finding raises the possibility that GRHL2 may be an
effective target for oral cancers.
There was strong elevation of TGF-β and its signaling
molecules in the tongue tissue of Grhl2 KO mice when
compared with the WT mice. While literature indicates
dual roles of TGF-β in cancer progression, TGF-β gen-
erally elicits tumor-suppressive effects during the early
stages of carcinogenesis by inducing cell cycle regulatory
proteins, e.g., p21WAF1, p14ARF, p16INK4A, and p57KIP,
leading to cellular senescence or apoptosis26–28. In addi-
tion, loss of Smad4 results in enhanced tumor growth and
anti-apoptotic pathways, and increased lymph node
metastasis in xenograft models29. Hence, the elevated
TGF-β signaling in the tongue tissues of the Grhl2 KO
mice would pose strong tumor-suppressive effects,
impeding the carcinogenic events induced by 4-NQO.
Prior study by Cieply et al. showed the suppressive effects
of GRHL2 on TGF-β-induced EMT in mammary epi-
thelial cells9. Likewise, in the current study, we demon-
strate the suppressive effect of GRHL2 on TGF-β
signaling in cultured OSCCs and oral epithelial tissues in
mice. In light of primary tumor development, this rela-
tionship between GRHL2 and TGF-β signaling further
supports the pro-carcinogenic effects of GRHL2 that have
been reported by several laboratories, including ours7, 30–
35. This relationship also determines the epithelial plasti-
city, which plays critical roles in tissue fibrosis, senes-
cence, wound healing, and cancer metastasis. We
previously showed that GRHL2 upregulates the expres-
sion of miR-200 family genes and other epithelial-specific
genes, e.g., p63, K14, E-Cad, and β-catenin, while it sup-
pressed mesenchymal regulators, e.g., fibronectin (FN), N-
Cad, ZEB1, and ZEB27. Many of these factors are also
woven into the TGF-β-signaling pathways to regulate the
epithelial plasticity; thus, the interactions between GRHL2
and TGF-β signaling are antagonistic. Interestingly, a
recent study showed inhibitory effects of GRHL2 on p300,
a transcription co-activator with histone acetyltransferase
activity, during tubulogenesis of kidney epithelial cells36.
Since p300 functions as a co-activator for TGF-β/Smad
signaling37, 38, p300 suppression may mediate the inhibi-
tory effects of GRHL2 on TGF-β signaling.
The current data also indicate that GRHL2 regulates
activation of the Erk and JNK MAP kinase pathways in
various cell types, including OSCC cells and NHOF.
Previous studies demonstrated the involvement of Erk
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and JNK in the carcinogenesis process. Immunohisto-
chemical survey revealed an elevated level of Erk in
OSCCs with higher grade of histopathology39. Ras-raf-
MEK-Erk signaling determines cancer cell proliferation
and survival, in part through negative regulation of p53
tumor suppressor network40, 41. A recent study showed
JNK activation as the possible etiology of Cetuximab
therapy resistance in head and neck squamous cell car-
cinomas (HNSCCs), which exhibit loss of Smad4 and
aggressive phenotype29. Hence, activation of MAP kinase
signaling has strong pro-carcinogenic effects, in part
through its crosstalk with TGF-β signaling. Alternatively,
JNK may elicit tumor-suppressive effects, as does GRHL2
in certain pathological context, in part depending on the
state of cancer progression7, 42. A recent study revealed a
role of JNK activation for anoikis, a specialized cell death
program induced by epithelial cell detachment, which
impedes cancer progression43. This newly discovered role
of JNK may be important for the effects of GRHL2 in
sensitizing cells to anoikis during reversion of EMT in
human mammary epithelial cells44.
Our data indicate that the TGF-β signaling and MAPK
pathways reciprocally converge through their functional
interactions with GRHL2, which maintains active MAP
kinase signaling and suppresses TGF-β signaling. Che-
mical inhibition of the MAP kinase pathway restored the
expression of the TGF-β-signaling molecules in the pre-
sence of GRHL2 overexpression. Therefore, the inhibitory
effects of GRHL2 on TGF-β signaling appear to be
mediated through activation of Erk and JNK signaling. We
also found increased phosphorylation and nuclear trans-
location of p65 in cells with GRHL2 knockdown, which
exhibited reduction in the p-Erk level. This provides
another layer of evidence to support the role of GRHL2 in
Erk regulation as prior studies demonstrate the inhibitory
effects of Erk on NF-κB activation24, 45. Direct effect of
GRHL2 in NF-κB signaling is not known, but our data at
least suggest inverse correlation between the two factors,
possibly through Erk signaling.
Although TGF-β can directly activate the MAP kinase
pathways, e.g., Erk, JNK, and p38, MAP kinase activation
via TGF-β-independent mechanism can suppress the
TGF-β signaling pathway. For instance, EGF-activated Erk
can directly phosphorylate Smad3 at Ser 207, Ser 203, and
Thr 178 residues, which suppress Smad transcriptional
activity46. Furthermore, Erk can directly phosphorylate
Smad4 and interfere with Smad4 interaction with R-
Smads, causing reduced transcriptional activity of TGF-β
target genes47. Hence, aberrant GRHL2 overexpression in
OSCCs may abrogate the TGF-β-mediated tumor-
suppressive effects through these biochemical effects of
MAP kinases. We propose a mechanistic model that
illustrates the functional interaction between GRHL2 and
TGF-β signaling pathway through Erk and JNK signaling
(Fig. 8). Generally, GRHL2 regulates epithelial phenotype
through direct transcriptional control of its target genes,
e.g., E-Cad, p63, hTERT, miR-200 family genes, and EDC
genes4, 5, 7. The current study revealed an alternative
pathway, in which GRHL2 determines epithelial
phenotype through activation of the MAP kinase signal-
ing, which then suppresses Smad-dependent TGF-β
signaling molecules. Further research will elucidate the
details by which GRHL2 controls the Erk and JNK MAP
kinases.
Materials and methods
Cells and cell culture
SCC4, SCC9, FaDu, and SCC15 cell lines were pur-
chased from the ATCC (Manassas, VA) and were cultured
in DMEM/Ham’s F-12 (Invitrogen, Carlsbad, CA) sup-
plemented with 10% fetal bovine serum (FBS) and 0.4 µg/
ml hydrocortisone. The cell lines have been authenticated
and tested for mycoplasma contamination. To over-
express GRHL2 in cells, we utilized a retroviral vector
(LXSN-GRHL2) expressing GRHL2 according to methods
described elsewhere7. Endogenous GRHL2 was knocked
down in SCC4 using the lentiviral vector (LV-ShGRHL2)
expressing shRNA against the GRHL2 target sequence or
the control lentiviral vector (LV-ShContr), as described
previously4, 20. GRHL2 was also knocked down in SCC15
and BaP-T cells using commercial GRHL2 shRNA vectors
(ShGRHL2-1, -2, -3) targeting different Grhl2 sequences
(Origene, Rockville, MD).
Fig. 8 Schematic representation for functional interaction
between GRHL2 and TGF-β signaling through MAP kinase
pathways. Mechanistic scheme is drawn to depict the functional
interaction between GRHL2 and TGF-β signaling through Erk and JNK
MAP kinase signaling. The current study identified an alternative
pathway by which GRHL2 regulates TGF-β signaling through
activation of the MAP kinase signaling pathways. This pathway is
distinct from the transcriptional regulation of the target genes, e.g., E-
cadherin, hTERT, p63, and miR-200 family genes, by direct GRHL2
binding at the promoter regions
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Generation of Grhl2 cKO mice
Epithelial tissue-specific Grhl2 cKO mice (denoted K14/
Grhl2 cKO) were generated by crossing Grhl2 floxed (fl/fl)
mice48 with the K14-CreERT mice (Jackson Laboratory,
Bar Harbor, ME)49. Grhl2 cKO was achieved with intra-
peritoneal (i.p.) administration of Tmx (75mg/kg) in 8-
week-old K14/Grhl2 cKO mice for 7 consecutive days to
induce homozygous deletion of Grhl2 in epithelial tissues.
Eight-week-old WT and KO mice (male and female,
20–26 g) were housed and monitored in individually
ventilated case system with ad libitum access to water and
food. Animal experiments were performed according to
the protocol approved by the UCLA Institutional Animal
Care and Use Committee. These WT and KO mice were
randomly allocated into different groups exposed to 4-
NQO or DMSO. To induce tongue SCC development,
Grhl2 WT (without Tmx) and Grhl2 KO mice were
exposed to 4-NQO (Sigma-Aldrich, St. Louis, MO) dis-
solved in DMSO and diluted in drinking water to a final
concentration of 30 μg/ml. For the 4-NQO assay, we only
included Grhl2 WT and KO, without heterozygotes.
Grhl2 WT or Grhl2 KO mice were maintained with or
without 4-NQO in drinking water for 16 weeks, followed
by 6 weeks of normal drinking water, as described pre-
viously50. We also administered Tmx after 4 or 16 weeks
of 4-NQO treatment. These mouse groups were labeled as
Tmx2 and Tmx3, respectively, to designate the time at
which Tmx was given to induce Grhl2 KO. Tmx1 denoted
the Grhl2 KO mice in which Tmx was administered right
before 4-NQO treatment. In total, there were Grhl2 WT
(n= 7), Grhl2 KO/Tmx1 (n= 6), Grhl2 KO/Tmx2 (n=
3), and Grhl2 KO/Tmx3 (n= 3; Table 1). In addition, we
included Grhl2 WT mice (n= 5) and Grhl2 KO mice (n
= 5), which were exposed to DMSO, as controls. The
number of mice were determined by pilot experiments
between Grhl2 WT and Grhl2 KO.
Quantitative reverse transcription-PCR analysis
Biopsies from mouse dorsal skin were punched and
immediately snap-frozen in liquid nitrogen and stored at
−80 °C until further processing. Total RNA was isolated
using the TRIzol Reagent (ThermoFisher Scientific,
Waltham, MA). DNA-free total RNA (5 μg) was used
for reverse transcription (RT) reaction followed by
quantitative PCR (qPCR) with LC480 SYBR Green I
master using universal cycling conditions in LightCycler®
480 (Roche, South San Francisco, CA). The primer
sequences were obtained from the Universal Probe
Library (Roche). The PCR cycling conditions were 45
cycles of 10 s at 95 °C, 45 s at 55 °C, and 20 s at 72 °C.
Second derivative Cq value determination method was
used to compare the fold differences. Cp is the cycle at
which the threshold is crossed. Experiments were per-
formed in triplicates.
Western blotting
Whole-cell extracts (WCEs) from the cultured cells and
mouse tissues (skin and tongue) were isolated using the
lysis buffer (1% Triton X-100, 20 mM Tris-HCl pH 7.5,
150mM NaCl, 1 mM EDTA, 1 mM EGTA, 2.5 mM
sodium pyrophosphate, 1 μM β-glycerophosphate, 1 mM
sodium orthovanadate, 1 mg/ml PMSF). WCEs were then
fractionated by SDS-PAGE and transferred to Immobilon
membrane (Millipore, Billerica, MA), which were incu-
bated successively with the primary and the secondary
antibodies, and exposed to the chemiluminescence
reagent (Amersham Pharmacia Biotech, Piscataway, NJ)
for signal detection. Each experiment was performed in
triplicate.
IHC and IFS analyses
Paraffin-embedded histological sections were stained
with H&E for determination of the histological changes in
epidermal and tongue epithelium in Grhl2 WT and KO
mice, and were analyzed without blinding by an oral
pathologist. Mouse oral mucosa and skin were fixed in 4%
(wt/vol) paraformaldehyde at 4 °C for 24 h. Samples were
embedded in paraffin, sectioned at 4 μm thickness, and
stained as described previously7. Numbers of positive
staining cells were counted and plotted as % of all cells in
at least 10 fields in each slide.
For IFS, cells were cultured in Nunc™ Lab-Tek™ II
Chamber Slide™ System (ThermoFisher Scientific) to
reach 70–80% confluence and fixed in 2% paraformalde-
hyde for 20min. Cells were permeabilized with 0.2%
Triton X-100 in phosphate-buffered saline (PBS) for 10
min, and then blocked for 1 h in PBS containing 2% FBS,
and incubated overnight at 4 °C with the primary anti-
body. After three washes with PBS, cells were incubated
with the secondary antibody for 1 h. Slides were mounted
in Prolong Gold w/DAPI (Invitrogen). Images were cap-
tured on an Olympus epifluorescence inverted micro-
scope (Olympus, Cypress, CA). IFS signals were
quantified via Image J software and the corrected total cell
fluorescence was calculated.
BrdU labeling
Keratinocyte proliferation was measured by intraper-
itoneal injection of BrdU (0.1 mg/g body weight in 0.9%
NaCl) 1 h before being killed. BrdU incorporation was
detected by IHC of paraffin-embedded sections using
anti-BrdU monoclonal antibody (Santa Cruz Biotechnol-
ogy, Santa Cruz, CA). The number of BrdU-positive and
total basal keratinocyte cells was counted in at least 10
areas in each slide.
Reagents
The following primary antibodies were used in this
study: GAPDH, ZEB1, E-Cad, FoxM1, HELLS, Cyclin B1,
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Cyclin D1, Cyclin A, K14, β-catenin, ZEB1, BrdU, and p63
from Santa Cruz Biotech; GRHL2 (Abnova, Taipei City,
Taiwan; H00079977-A01); N-Cad from BD Biosciences
(San Jose, CA); FN and Snail from Sigma-Aldrich; p-
Smad3 (ser423/425), p-Smad2 (ser465/467), Smad4, p-
p38 (Thr180/Tyr182), p-Erk1/2 (Thr202/Tyr204), p-JNK
(Thr183/Tyr185), p-p65 (Ser536), and Oct-4 from Cell
Signaling Technology Inc. (Danvers, MA); hTERT and
Sox2 from Abcam (Cambridge, MA); TGF-β from Novus
(Littleton, CO); and PCNA from Calbiochem (San Diego,
CA). Secondary peroxidase-conjugated anti-rabbit or
anti-mouse antibodies were from Jackson ImmunoR-
esearch Laboratories Inc. (West Grove, PA). Tmx and 4-
NQO were purchased from Sigma-Aldrich, while TGF-β1
was from PeproTech Inc. (Rocky Hill, NJ). JNK selective
inhibitor SP600125 was purchased from Sigma-Aldrich
and MEk1/2 inhibitors U0126 and PD98059 were from
Cell Signaling Technology Inc.
Statistical analysis
Statistical analysis was performed using Student’s t-test
(two-tailed) for the quantitative reverse transcription-PCR
gene expression and BrdU labeling, western blotting, and
immunostaining experiments. P values o 0.05 were
considered significant. All data are expressed as mean ±
SD. Statistical differences between the number of tumor
nodules in WT mice and different groups of KO mice
exposed to 4-NQO were evaluated by the non-
parametrical Wilcoxon rank-sum test for each pair of
groups. The number of mice in each group was deter-
mined by phenotypic changes observed with Grhl2 defi-
ciency in the cell lines7, 20.
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